Related Experiment Video
Updated: Jun 12, 2026
11:37
Zika Virus Specific Diagnostic Epitope Discovery
Published on: December 12, 2017
Immuno-μSARS2 Chip: A Peptide-Based Microarray to Assess COVID-19 Prognosis Based on Immunological Fingerprints
Julian Guercetti1,2, Marc Alorda1,2,3,4, Luciano Sappia1,2
1Nanobiotechnology for Diagnostics Group, Instituto de Química Avanzada de Cataluña, IQAC-CSIC, C/Jordi Girona 18-26, 08034 Barcelona, Spain.
ACS Pharmacology & Translational Science
|March 20, 2025
Summary
A new microarray chip, Immuno-μSARS2, analyzes COVID-19 patient immune responses. It accurately predicts disease progression, including hospitalization and intensive care unit (ICU) admission, aiding clinical decisions.
Area of Science:
- Immunology
- Infectious Diseases
- Biotechnology
Background:
- COVID-19 prognosis remains challenging, necessitating advanced diagnostic tools.
- Understanding the immunological response to SARS-CoV-2 is crucial for predicting disease severity.
- Existing diagnostic methods may not fully capture the nuances of patient immune profiles for prognostic purposes.
Purpose of the Study:
- To develop and validate a multiplexed microarray chip (Immuno-μSARS2) for assessing COVID-19 patient prognosis.
- To analyze the avidity of patient sera against SARS-CoV-2 peptide epitopes and proteins.
- To correlate immunological signatures with clinical outcomes such as hospitalization, ICU admission, and mortality.
Main Methods:
- Development of a multiplexed fluorescent microarray platform (Immuno-μSARS2) with 28 peptide epitopes and 7 proteins.
- Design and synthesis of 12-15 mer peptide epitopes from Spike and Nucleocapsid proteins.
- Analysis of 755 human serum samples from three independent cohorts using the Immuno-μSARS2 chip.
- Computational analysis to correlate immunological signatures with clinical outcomes.
Main Results:
- The Immuno-μSARS2 chip demonstrated 98% specificity and 91% sensitivity in identifying RT-PCR+ patients.
- Accurate prediction rates were achieved for critical outcomes: 82% for mortality (exitus), 80% for ICU admission, and 73% for hospitalization.
- The platform allows high-throughput analysis of 96 samples in 90 minutes using only 10 μL of serum.
Conclusions:
- The Immuno-μSARS2 chip is a valuable tool for predicting COVID-19 progression and assisting clinical decision-making.
- This diagnostic approach offers a rapid, sensitive, and specific method for evaluating patient immune responses.
- The technology has potential for broad application in diagnosing and managing other infectious diseases.
